Allergen-specific immunotherapy with recombinant grass pollen allergens

Journal of Allergy and Clinical Immunology

Volumn 116, Issue 3, 2005, Pages 608-613

  Jutel, Marek ^a   Jaeger, Lothar ^b   Suck, Roland ^c   Meyer, Hanns ^c   Fiebig, Helmut ^c   Cromwell, Oliver ^c  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c ALLERGOPHARMA JOACHIM GANZER KG   (Germany)

Author keywords

Allergen; Allergic rhinitis; Allergy; Grass pollen; Immunotherapy; Recombinant allergens

Indexed keywords

ALLERGEN; GRASS POLLEN EXTRACT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; PLACEBO; RECOMBINANT PROTEIN;

ADULT; ALLERGY; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; ASTHMA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; DRUG SPECIFICITY; FEMALE; HEALTH STATUS; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROVOCATION TEST; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; ALLERGENS; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MALE; POACEAE; POLLEN; RECOMBINANT PROTEINS; RHINITIS, ALLERGIC, SEASONAL;

EID: 24644509434     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2005.06.004     Document Type: Article

References (38)

1. J. Bousquet, R.F. Lockey, and H.J. Malling WHO position paper: allergen immunotherapy: therapeutic vaccines for allergic diseases: Geneva, January 27-29, 1997 Allergy 53 suppl 44 1998 4 42
2. J. Bousquet, H. Maasch, B. Martinot, A. Hejjaoui, R. Wahl, and F.B. Michel Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids, II: comparison between parameters assessing the efficacy of immunotherapy J Allergy Clin Immunol 82 1988 439 446
3. J. Bousquet, H.J. Maasch, A. Hejjaoui, W. Skassa-Brociek, R. Wahl, and H. Dhivert Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids, III: efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma J Allergy Clin Immunol 84 1989 546 556
4. V.A. Varney, M. Gaga, A.J. Frew, V.R. Aber, A.B. Kay, and S. Durham Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs BMJ 302 1991 265 269
5. C.J. Corrigan, J. Kettner, C. Doemer, O. Cromwell, and A. Narkus Efficacy and safety of preseasonal immunotherapy with an aluminium-adsorbed six-grass pollen allergoid Allergy 60 2005 801 807
6. P.A. Eng, M. Reinhold, and H.E. Gnehm Long-term efficacy of preseasonal grass-pollen immunotherapy in children Allergy 57 2002 306 311
7. S.R. Durham, S.M. Walker, E.M. Varga, M.R. Jacobson, F. O'Brien, and W. Noble Long-term clinical efficacy of grass-pollen immunotherapy N Engl J Med 341 1999 468 475
8. K. Andersson, and J. Lidholm Characteristics and immunobiology of grass pollen allergens Int Arch Allergy Immunol 130 2003 87 107
9. C. Suphioglu What are the most important allergens in grass pollen that are linked to human allergic disease? Clin Exp Allergy 30 2000 1335 1341
10. R. Valenta The future of antigen-specific immunotherapy of allergy Nat Rev Immunol 2 2002 446 453
11. European Agency for the Evaluation of Medicinal Products. CPMP/ICH/135/95 note for guidance on good clinical practice 1997. Available at: http://www.emea.eu.int/pdfs/human/ich/013595en.pdf. Accessed January 15, 2005.
12. National Institutes of Health. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2004. NIH publication number 02-3659. Available at: http://www.ginasthma.com. Accessed January 15, 2005.
13. O. Cromwell, R. Suck, H. Kahlert, A. Nandy, B. Weber, and H. Fiebig Transition of recombinant allergens from bench to clinical application Methods 32 2004 300 312
14. B. Trivedi, C. Valerio, and E. Slater Endotoxin content of standardized allergen vaccines J Allergy Clin Immunol 111 2003 777 783
15. E.F. Juniper, and G.H. Guyatt Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis Clin Exp Allergy 21 1991 77 83
16. H.J. Malling Methodology and quality of immunotherapy trials Allergy 59 2004 482 484
17. H.-J. Malling Allergen immunotherapy efficacy in rhinitis and asthma Allergy Clin Immunol Int 16 2004 92 95
18. J. Bousquet, P. van Cauwenberge, and N. Khaltaev Allergic rhinitis and its impact on asthma. ARIA workshop report J Allergy Clin Immunol 108 2001 S147 S334
19. H.J. Malling Immunotherapy as an effective tool in allergy treatment Allergy 53 1998 461 472
20. E.F. Juniper, G.H. Guyatt, L.E. Griffith, and P.J. Ferrie Interpretation of rhinoconjunctivitis quality of life questionnaire data J Allergy Clin Immunol 98 1996 843 845
21. E.F. Juniper, A.K. Thompson, P.J. Ferrie, and J.N. Roberts Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire Clin Exp Allergy 30 2000 132 140
22. H. Riechelmann, B. Epple, and G. Gropper Comparison of conjunctival and nasal provocation test in allergic rhinitis to house dust mite Int Arch Allergy Immunol 130 2003 51 59
23. C. Moller, and S. Dreborg Cross-reactivity between deciduous trees during immunotherapy, I: in vivo results Clin Allergy 16 1986 135 143
24. U. Bodtger, L.K. Poulsen, H.H. Jacobi, and H.J. Malling The safety and efficacy of subcutaneous birch pollen immunotherapy: a one-year, randomized, double-blind, placebo-controlled study Allergy 57 2002 297 305
25. M. Akdis, J. Verhagen, A. Taylor, F. Karamloo, C. Karagiannidis, and R. Crameri Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen specific T regulatory 1 and T helper 2 cells J Exp Med 199 2004 1567 1575
26. E.M. Ling, T. Smith, X.D. Nguyen, C. Pridgeon, M. Dallman, and J. Arbery Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease Lancet 363 2004 608 615
27. M. Jutel, M. Akdis, F. Budak, C. Aebischer-Casaulta, M. Wrzyszcz, and K. Blaser IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy Eur J Immunol 33 2003 1205 1214
28. C.A. Akdis, and K. Blaser Il-10 induced anergy in peripheral T cells and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy FASEB J 13 1999 603 609
29. K.T. Nouri-Aria, P.A. Wachholz, J.N. Francis, M.R. Jacobson, S.M. Walker, and L.K. Wilcock Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity J Immunol 172 2004 3252 3259
30. J.N. Francis, S.J. Till, and S.R. Durham Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy J Allergy Clin Immunol 111 2003 1255 1261
31. P.A. Wachholz, E. Kristensen Soni, S.J. Till, and S.R. Durham Inhibition of allergen IgE-binding to B cells by IgG antibodies after grass pollen immunotherapy J Allergy Clin Immunol 112 2003 915 922
32. C.L. Hardy, J.M. Rolland, and R.E. O'Hehir Blocking antibodies in immunotherapy: the Ying and the Yang Clin Exp Allergy 34 2004 510 512
33. R.E. Rossi, and G. Monasterolo Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)-specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients Int Arch Allergy Immunol 135 2004 44 53
34. R. Moverare, L. Elfman, E. Vesterinen, T. Metso, and T. Haahtela Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System Allergy 57 2002 423 430
35. L. Winther, H.J. Malling, and H. Mosbech Allergen specific immunotherapy in birch- and grass-pollen-allergic rhinitis, II: side-effects Allergy 55 2000 827 835
36. M.A. Greenberg, C.R. Kaufman, G.E. Gonzales, C.D. Rosenblatt, L.J. Smith, and R.J. Summers Late and immediate systemic-allergic reactions to inhalant allergen immunotherapy J Allergy Clin Immunol 77 1986 865 870
37. C. Moreno, J. Cuesta-Herranz, L. Fernández-Távora, and E. Alvarez-Cuesta Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases Clin Exp Allergy 34 2004 527 531
38. L. Kazemi-Shirazi, V. Niederberger, B. Linhart, J. Lidholm, D. Kraft, and R. Valenta Recombinant marker allergens: diagnostic gatekeepers for the treatment of allergy Int Arch Allergy Immunol 127 2002 259 268